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Background and Purpose Widespread use of thrombolytic treatments, along with improved 
chances of survival after an initial ischemic stroke, increases the possibility of repeated 
thrombolysis. There are few reports, however, regarding repeated thrombolysis in patients 
who have suffered acute ischemic stroke. We explored the number and outcome of patients 
with repeated thrombolytic therapy in the era of multimodal thrombolytic treatments.
Methods We investigated patients with acute ischemic stroke who had received thrombo-
lytic treatments for a period of 10 years. Number of thrombolysis was determined in each 
patient. Recanalization was defined as Thrombolysis in Cerebral Infarction grading ≥2a. 
Symptomatic hemorrhagic transformation was defined as any increase in the National Insti-
tutes of Health Stroke Scale score that could be attributed to intracerebral hemorrhage. A 
good outcome was defined as a modified Rankin scale score ≤2.
Results Of the 437 patients who received thrombolytic treatments, only 7 underwent re-
peated thrombolysis (1.6%). The median age at the time of repeated thrombolytic therapy 
was 71 years old; 4 of the patients were female. All patients had 1 or more potential sources 
of cardiac embolism. Recanalization was achieved in all patients, in both the first and the 
second thrombolysis. No symptomatic intracranial hemorrhage occurred after repeated 
thrombolytic treatments. Five patients (71.4%) showed good outcomes at 3 months.
Conclusions Repeated thrombolysis for recurrent acute ischemic stroke appears to be safe 
and feasible. Among patients who experience recurrent acute ischemic stroke, thrombolytic 
therapy could be considered even if the patient has had previous thrombolytic treatments.
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Introduction
The possibility of repeated thrombolysis has increased be-
cause of the widespread use of thrombolytic treatments, an im-
proved chance of survival after thrombolytic treatment, and an 
increase in life expectancy.1,2 In myocardial infarction and pul-
monary embolism, repeated thrombolytic therapy using intra-
venous recombinant tissue plasminogen activator (rt-PA) has 
been reported to be safe and effective.3-5 However, repeated 
thrombolytic therapy in patients with acute ischemic stroke is 
rarely reported, and almost all previous reports were of patients 
who received intravenous rt-PA.2,6-8 Only 1 case report detailed 
a successful endovascular treatment for recurrent basilar artery 
occlusions.9 Recently, multimodal thrombolytic therapy, which 
includes intravenous and intra-arterial thrombolytic drugs and 
mechanical thrombectomy, has been introduced and is fre-
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quently used by stroke teams.10-13 The goals of this study are to 
1) identify how frequently repeated thrombolytic treatments 
are performed since the existence of multimodal thrombolytic 
treatments, and 2) characterize the safety and outcome of re-




We drew subjects for this study from the Yonsei Stroke Regis-
try.14 We selected patients with acute ischemic stroke who had 
received thrombolytic treatments within a 10-year period (from 
August 2001 to July 2011). Frequency of thrombolysis was de-
termined in each patient, and initial stroke severity was assessed 
by National Institutes of Health Stroke Scale (NIHSS) scores. 
Potential cardiac sources of embolism were defined according 
to the Trial of ORG 10172 in the Acute Stroke Treatment clas-
sification.15 This study was approved by the Severance Hospital 
Institutional Review Board of Yonsei University Health System 
(4-2012-0553).
Thrombolytic therapy
The detailed protocol for thrombolytic treatment has been 
previously reported.16-19 Thrombolytic treatment was performed 
using intravenous rt-PA (Actilyse, Boehringer Ingelheim, Ger-
many), intra-arterial urokinase (Urokinase, Yuhan, Seoul, Ko-
rea), or intra-arterial mechanical devices (microwire, Agility 10, 
Cordis, Miami, Fla., USA; Penumbra, Alameda, CA, USA; Soli-
taire, ev3 Inc, Irvine, CA, USA). Inclusion and exclusion criteria 
for thrombolytic treatments were based on previous trials.20,21 
Patients who could be treated within 3 hours after the onset of 
symptoms received intravenous rt-PA (0.9 mg/kg with 10% bo-
lus injection, followed by continuous infusion of the remainder 
over 60 minutes). After intravenous rt-PA infusion, further treat-
ment with intra-arterial urokinase or mechanical thrombectomy 
was permitted for patients who showed an unsatisfactory clinical 
response (improvement on the NIHSS score < 50%).19,22 Pa-
tients who could be treated within 3-6 hours after symptom on-
set were considered for intra-arterial urokinase (up to 1 million 
units) or mechanical thrombectomy. Abciximab was also al-
lowed in patients with reocclusion.16
Assessment of outcomes
Recanalization was evaluated at 24 ± 4 hours after thromboly-
sis using magnetic resonance angiography or computed tomog-
raphy angiography. The Thrombolysis in Cerebral Infarction 
(TICI) grading system (Grade 0: no perfusion; Grade 1: pene-
tration with minimal perfusion; Grade 2a: partial filling 2/3 of 
the entire vascular territory; Grade 2b: complete filling, but the 
filling is slower than normal; Grade 3: complete perfusion) was 
used to assess the success or failure of recanalization.23 Success-
ful recanalization was defined as TICI ≥ 2a. Hemorrhagic trans-
formations were assessed by computed tomography or magnetic 
resonance imaging at 24 ± 4 hours after thrombolysis, or when-
ever clinical deterioration was suspected. Symptomatic hemor-
rhagic transformation was defined as any increase in the NIHSS 
score that could be attributed to intracerebral hemorrhage 
(ICH) on brain imaging studies.20 Independent neurologists de-
termined functional outcomes at 3 months with the modified 
Rankin scale (mRS). A good outcome was defined as an mRS 
score ≤ 2.
Statistical analysis
Data were analyzed using SPSS 18.0 (SPSS, Chicago, IL, 
USA) for Windows. The Pearson chi-square test or Fisher’s ex-
act test was used to compare frequencies. For continuous vari-
ables, data distributions were examined for normality using the 
Kolmogorov-Smirnov test. Provided that the data did not devi-
ate from normal distribution, the mean and standard deviation 
were calculated and parametric tests (independent sample t-
tests) were applied. For data that were not normally distributed, 
we report descriptive statistics as the median and interquartile 
range; these were compared using non-parametric Mann-Whit-
ney U tests. A P-value less than 0.05 was considered significant.
Results
Characteristics of patients with repeated thrombolysis
During the 10-year study period, a total of 437 patients with 
acute ischemic stroke underwent thrombolytic therapy. Of 
these, a total of 7 patients (1.6%) received thrombolytic therapy 
twice in chronologically separate events. Table 1 summarizes 
the demographic and clinical characteristics of the patients with 
repeated thrombolysis. The median age for patients who re-
ceived repeated thrombolytic therapy was 71 years old, and 4 
patients were female. The median time interval between the 
first and second thrombolytic treatment was 16 months (rang-
ing from 6 days to 76 months). The median time from the on-
set of symptoms to thrombolytic therapy was 120 hours for the 
first thrombolytic treatment, and 125 hours for the repeated 
treatment. Initial median NIHSS scores were 12 for the first 
treatment and 15 for the repeated treatment. The occluded ce-
rebral arteries were the middle cerebral arteries in 6 patients 
and the internal carotid artery in 1 patient. In the second attack, 
all of the patients experienced the occlusion in the same cerebral 
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arteries as the first ischemic strokes. However, the right and left 
sides of the particular arteries were reversed for 4 patients in the 
second attack. In the first thrombolytic treatment, the treatment 
modalities were intravenous rt-PA in 4 patients, intra-arterial 
urokinase in 3 patients, and mechanical treatments in 3 patients. 
Multimodal treatments were performed in 2 patients. In the sec-
ond thrombolytic treatment, 5 patients were treated with intra-
venous rt-PA, 3 with intra-arterial urokinase, and 5 with me-
chanical treatments. Four patients were treated using multimod-
al treatments. All patients who received repeated thrombolytic 
treatments had 1 or more potential sources of cardiac embolism. 
After the first thrombolysis, recanalization was achieved in all 
patients (TICI 3 in 2 patients and 2b in 4 patients) with no 
symptomatic ICHs. Five (71.4%) out of 7 patients showed good 
outcome after 3 months (mRS 0 in 4 patients, mRS 1 in 1, and 
mRS 4 in 2). Similar to the first thrombolysis, after the second 
thrombolysis, recanalization was achieved in all patients and no 
symptomatic ICH occurred. All patients recovered to the base-
line mRS score for the first thrombolytic treatment.
Comparison between single and repeated 
thrombolysis
To examine safety and outcome of patients with repeated 
thrombolysis, the data of 430 patients who were given a single 
thrombolytic treatment were compared. Age, sex, initial stroke 
severity, door to admission time, initial systolic blood pressure 
and glucose level, and risk factors including hypertension, dia-
betes mellitus, hypercholesterolemia, and smoking, were not 
Table 1. Demographic characteristics of patients who received repeated thrombolytic treatment
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Sex Female Male Female Female Male Male Female
First thrombolysis
   Age 50 70 73 74 56 67 75
   Onset to treatment (min) 420 150 70 120 316 70 100
Risk factors
   Hypertension (-) (+) (-) (+) (+) (+) (-)
   Diabetes mellitus (-) (-) (+) (-) (+) (+) (-)
   Hypercholesterolemia (-) (-) (-) (-) (-) (-) (+)
   Smoking (-) (-) (-) (-) (-) (-) (-)
Initial NIHSS score 8 16 12 7 15 6 14
Occluded artery Right ICA Left MCA Left MCA Left MCA Right MCA Right MCA Left MCA
Treatment modalities
   IV rt-PA (mg) None None 54 40 None 60 53.6
   IA UK (Unit) None 300,000 100,000 None 260,000 None None
   Mechanical Solitaire Microwire Microwire None None None None
Outcomes
   Recanalization (TICI ≥ 2a) 3 2b 2b 3 2b 3 2b
   Symptomatic ICH None None None None None None None
   mRS at 3 months 0 4 0 0 1 0 4










A-fib, MS LA 
swirling
Second thrombolysis
   Time interval between first and 
      second treatment
6 days 6 months 3 months 16 months 76 months 47 months 37 months
   Onset to treatment (min) 72 169 55 125 300 67 150
   Initial NIHSS score 18 13 12 22 15 19 15
   Occluded artery Left ICA Right MCA Left MCA Left MCA Right MCA Left MCA Right MCA
Treatment modalities
   IV rt-PA (mg) None 66 52.2 41.4 None 68 63
   IA UK (Unit) None 700,000 None None 500,000 240,000 None
   Mechanical Solitaire Microwire None Solitaire None Microwire Solitaire
Outcome
   Recanalization (TICI ≥ 2a) 3 2b 2b 3 2a 2b 2b
   Symptomatic ICH None None None None None None None
   mRS at 3 months 0 4 0 0 1 0 4
A-fib, atrial fibrillation; IA UK, intra-arterial urokinase; ICA, internal carotid artery; ICH, intracranial hemorrhage; IV rt-PA, intravenous recombinant tissue plasminogen activator; 
LAA, left atrial appendage; LA, left atrium; MCA, middle cerebral artery; MS, mitral stenosis; MVP, mitral valve stenosis; mRS, modified Rankin scale; NIHSS, the National In-
stitute of Health Stroke Scale; TICI, Thrombolysis in Cerebral Infarction.
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different between patients with single and repeated treatments. 
The frequency of potential sources of cardiac embolism, how-
ever, was different (100% in the repeated thrombolytic treat-
ment vs. 59.6% in the single treatment, P = 0.045). Among the 
thrombolytic modalities, mechanical thrombolysis was more 
commonly performed in patients with repeated treatments 
(71.4% vs. 38.4%, P = 0.027). Outcome variables, including re-
canalization, symptomatic ICH, and good outcome were simi-
lar (Table 2).
Discussion
This study demonstrates that repeated thrombolytic treat-
ments for recurrent ischemic strokes is safe and feasible. In 10 
years, only 1.6% of all thrombolyzed patients underwent re-
peated thrombolysis. All repeatedly treated patients had 1 or 
more sources of cardiac embolism and achieved recanalization 
without symptomatic ICH in the first thrombolytic treatment. 
On repeated thrombolysis, these patients were recanalized 
again without symptomatic ICH, and all recovered to the base-
line neurological state of the first thrombolytic treatment. Com-
pared to the patients who had a single treatment, the rate of me-
chanical thrombectomy was twice as high in patients with re-
peated treatments. The outcome of patients with repeated 
thrombolysis was similar that of patients with only one throm-
bolysis.
In acute myocardial infarction or pulmonary embolism, re-
peated thrombolysis has been reported to be safe and feasible.3-5 
In the case of acute ischemic stroke, however, its effectiveness is 
largely unknown. The major risk of thrombolytic treatment in 
ischemic stroke is ICH.24 Because the brain-blood barrier is dis-
rupted in previously infarcted tissue, repeated thrombolytic 
treatments may pose a greater possibility for ICH. Few investi-
gators have reported multiple administrations of thrombolytic 
drugs for recurrent ischemic strokes.2,6-8 A case series of repeated 
thrombolytic therapy from a German stroke database showed 
that 9 (1.8%) out of 496 thrombolyzed patients were repeatedly 
treated with intravenous rt-PA for chronologically separate acute 
ischemic strokes over a 4-year period.2 In that study, the median 
time span between the first and second thrombolysis was 10 
months (range, 3 to 48), 67% of patients had favorable out-
comes, and no symptomatic ICH occurred. These rates of re-
peated treatments and outcomes are similar to the current study.
Current guidelines recommend that a stroke in the prior 3 
months is considered an exclusionary criterion for intravenous 
rt-PA.24 This recommendation, however, is derived from clini-
cal trials for acute myocardial infarction, and the information on 
acute ischemic stroke is limited.25 Repeated use of rt-PA after 1 
day theoretically will not lead to toxic plasma levels because the 
half-life of rt-PA is 6 min, and more than 80% of rt-PA is elimi-
nated via urine within 18 h after administration.26,27 There are 
only 4 case reports of repeated thrombolytic therapy within 3 
months, where the time interval between the first and second 
thrombolysis was 24 to 90 hours.7-9,28 Three of those patients 
received intravenous rt-PA, and the remaining patient under-
went intra-arterial chemical and mechanical thrombolysis. All 
patients showed good outcomes without symptomatic ICH. In 
our data, 1 patient received the second thrombolysis within 6 
days (patient 1). Cardioembolic occlusion occurred on the 
right internal carotid artery in the first stroke, and recurrent oc-
clusion on the left internal carotid artery in the second stroke. 
Both thrombi were completely removed using the Solitaire de-
vices, and no chemical thrombolytic agents were used. This pa-
tient fully recovered. Therefore, further study of patients with 
prior stroke in the previous 3 months is needed and may in-
crease the number of eligible patients.
Immunologic reactions following repeated thrombolysis are 
another concern. In patients with myocardial infarction, repeat-
Table 2. Comparison between patients with a repeated treatment and pa-








Age (yr) 71 (62-75) 67.5 (60-75) 0.601
Sex (male) 3 (42.9) 270 (62.8) 0.433
Initial NIHSS score 15 (12-19) 15 (10-20) 0.802
Onset to treatment (min) 125 (67-169) 105.5 (53-140) 0.629
Any PCSE 7 (100) 258 (59.6) 0.045
Past history
   Hypertension 4 (57.1) 297 (69.1) 0.682
   Diabetes mellitus 3 (42.9) 116 (27.0) 0.396
   Hypercholesterolemia 1 (14.3) 58 (13.5) 1.000
   Smoking 0 (0.0) 90 (20.9) 0.353
   Atrial fibrillation 6 (85.7) 201 (46.7) 0.056
   Initial SBP (mmHg) 150 (123-154) 150 (133-170) 0.300
   Initial glucose (mg/dL) 127 (109-141) 125 (108-158) 0.998
Mode of thrombolysis
   IV rt-PA only 1 (14.3) 180 (41.9) 0.634
   IA UK only 1 (14.3) 85 (19.8) 0.337
   Mechanical treatment only 1 (14.3) 11 (2.6) 0.405
   Any mechanical treatment 5 (71.4) 165 (38.4) 0.027
   Multimodal treatment 4 (57.1) 154 (35.8) 0.451
Outcome
   Recanalization (TICI ≥  2a) 7 (100.0) 312 (72.6) 0.197
   Symptomatic ICH 0 (0.0) 56 (13.0) 0.603
   Good outcome (mRS 0-2) 5 (71.4) 221 (51.4) 0.451
Values are given as median with IQR or number with percentage.
IA UK, intra-arterial urokinase; ICH, intracranial hemorrhage; IV rt-PA, intravenous 
recombinant tissue plasminogen activator; mRS, modified Rankin scale; NIHSS, the 
National Institute of Health Stroke Scale; PCSE, potent cardiac source of embolism; 
SBP, systolic blood pressure; TICI, Thrombolysis in Cerebral Infarction.
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ed administration of streptokinase is not recommended because 
of its antigenicity.29 Although rt-PA and urokinase are endoge-
nous proteins and are considered non-antigenic, several studies 
have reported the development of antibodies against rt-PA and 
allergic reactions after rt-PA administrations.30-32 Furthermore, 
activation of fibrinolysis may facilitate anaphylactoid reactions.33 
Previous reports did not show any immunological reactions in 
patients who were given repeated treatments.2 Although we did 
not check titers of antibodies, our 5 patients who received re-
peated treatments with rt-PA or urokinase did not show any 
symptoms or signs of an immunological reaction.
It is noteworthy that all patients who received repeated throm-
bolytic treatments had 1 or more sources of cardiac embolism, 
most of which were atrial fibrillation. Recurrent ischemic stroke 
after intravenous rt-PA in patients with sources of cardiac embo-
lism is common.28,34,35 Higher recurrence of ischemic stroke in 
patients with cardiac embolic sources may be connected to the 
increased likelihood of receiving repeated thrombolysis for those 
patients. Currently, clinical trials of new anticoagulants yield fa-
vorable results and have been adopted for patients with non-val-
vular atrial fibrillation.36 Recent guidelines for thrombolytic 
treatments also allow intravenous rt-PA use in patients who are 
currently taking a direct thrombin inhibitor or factor Xa inhibi-
tors with normal coagulation laboratory tests.24 Further study is 
needed to investigate proper treatments for recurrent stroke in 
patients with new anticoagulants.
Several limitations exist in this study. First, although our data 
were collected from consecutive patients of a single stroke team 
over 10 years, the number of patients with repeated thrombo-
lytic treatment were small. Considering the similar frequency of 
repeated thrombolysis in a different stroke database,2 it can be 
assumed that repeated thrombolysis is rarely performed. Sec-
ond, our data do not enable us to draw conclusions about the 
optimal thrombolytic modality in repeated cases. In this study, 
mechanical thrombectomy in repeated treatment was twice as 
likely to be performed. Thrombolytic modality in each case was 
decided according to predefined protocol; however, conditions 
including age, stroke severity, occluded cerebral arteries, under-
lying medical conditions, and medication may influence the se-
lection of thrombolytic modality for repeated events. The ad-
vancement of mechanical devices for acute ischemic stroke may 
allow for more safe and favorable outcomes in repeated throm-
bolytic treatments.10,12 Third, we examined the safety and out-
come of patients with repeated thrombolysis through compari-
son to those with single thrombolytic treatment. Caution must 
be taken in interpreting these results. Because the number of 
cases was small, the number of severe strokes was not large, and 
the thrombolysis modalities were heterogeneous, the negative 
results from this comparison cannot be regarded as evidence 
for the safety and feasibility of repeated thrombolytic treat-
ments. Further prospective study is warranted.
Conclusion
Our study investigated the safety and outcome of patients 
with repeated thrombolysis in the era of multimodal thrombo-
lytic treatments. Although it is rarely performed, repeated 
thrombolysis appears to be safe and feasible for patients with 
recurrent acute ischemic stroke. Repeated thrombolytic therapy 
could be considered, even if patients have had previous history 
of thrombolytic treatments.
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